The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

J Virol. 1996 Feb;70(2):820-9. doi: 10.1128/JVI.70.2.820-829.1996.

Abstract

The Vpu protein is a human immunodeficiency virus type 1 (HIV-1)-specific accessory protein that is required for the efficient release of viral particles from infected cells. Even though HIV-2 does not encode Vpu, we found that this virus is nevertheless capable of efficiently releasing virus particles. In fact, the rate of virus release from HeLa cells transfected with a full-length molecular clone of HIV-2, ROD10, was comparable to that observed for the vpu+ HIV-1 NL4-3 isolate and was not further enhanced by expression of Vpu in trans. However, consistent with previous observations showing that HIV-2 particle release is Vpu responsive in the context of HIV-1/HIV-2 chimeric constructs; exchanging the gag-pol region of NL4-3 with the corresponding region from pROD10 rendered the resulting chimeric virus Vpu responsive. Our finding that the responsiveness of HIV-2 particle release to Vpu is context dependent suggested the presence of a Vpu-like factor(s) encoded by HIV-2. Using chimeric proviruses encoding HIV-2 gag and pol in the context of the HIV-1 provirus that were coexpressed with subgenomic HIV-2 constructs, we found that the HIV-2 envelope glycoprotein had the ability to enhance HIV-2 particle release with an efficiency comparable to that of the HIV-1 Vpu protein. Conversely, inactivation of the HIV-2 env gene in the original ROD10 clone resulted in a decrease in the rate of viral particle release to a level that was comparable to that of Vpu-deficient HIV-1 isolates. Providing the wild-type envelope in trans rescued the particle release defect of the ROD10 envelope mutant. Thus, unlike HIV-1, which encodes two separate proteins to regulate virus release or to mediate viral entry, the HIV-2 Env protein has evolved to perform both functions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Brefeldin A
  • Cyclopentanes / pharmacology
  • Gene Products, nef / metabolism
  • Gene Products, vif / metabolism
  • Gene Products, vpr / metabolism
  • Genes, Viral
  • Glycoproteins / drug effects
  • Glycoproteins / genetics
  • Glycoproteins / metabolism*
  • HIV Seropositivity / blood
  • HIV Seropositivity / immunology
  • HIV-2 / metabolism*
  • Human Immunodeficiency Virus Proteins
  • Humans
  • Mutation
  • Viral Envelope Proteins / drug effects
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / metabolism*
  • Viral Regulatory and Accessory Proteins / drug effects
  • Viral Regulatory and Accessory Proteins / metabolism*
  • Virion / metabolism
  • nef Gene Products, Human Immunodeficiency Virus
  • vif Gene Products, Human Immunodeficiency Virus
  • vpr Gene Products, Human Immunodeficiency Virus

Substances

  • Cyclopentanes
  • Gene Products, nef
  • Gene Products, vif
  • Gene Products, vpr
  • Glycoproteins
  • Human Immunodeficiency Virus Proteins
  • VPX protein, Human immunodeficiency virus 2
  • Viral Envelope Proteins
  • Viral Regulatory and Accessory Proteins
  • nef Gene Products, Human Immunodeficiency Virus
  • vif Gene Products, Human Immunodeficiency Virus
  • vpr Gene Products, Human Immunodeficiency Virus
  • vpu protein, Human immunodeficiency virus 1
  • Brefeldin A